Index
A
accountability and management, 62–75
see also finance
acronyms and abbreviations list, 169–171
administered finances, 81–82
special accounts, 79
administrative tribunal decisions, 67
advertising and market research, 157
age demographic of staff, 72
agency resource statements, 161–162
annual report errata, 160
annual report list of requirements, 163–168
apheresis, 26, 33, 151
assets and asset management, 81, 83
administered items, 82
Audit Committee, 63, 64, 149
Australian Bleeding Disorders Registry (ABDR), 40, 42, 63
MyABDR portal, 42–43
Australian Commission on Safety and Quality in Health Care (ACSQHC), 53, 55
Australian Haemophilia Centre Directors’ Organisation (AHCDO), 48
Australian Information Commissioner, 67
Australian National Audit Office (Auditor-General, ANAO), 63, 67
Australian Public Service Commission Employee Census, 69
Australian Red Cross Blood Service (Blood Service), 18, 32–34
annual meeting with NBA Board, 13
NMF (Blood and Blood Products) Special Account, 78, 79
Review of Risk Management in the Blood Sector, 41
see also fresh blood
B
balance sheet, 81
Baxalta Australia Pty Ltd, 46
immunoglobulins (IVIg), 22, 35, 36, 154
plasma and recombinant products, 22, 36, 37, 152, 153, 154
Bayer Australia Limited, 23, 37, 153
best practice tools, 49
Bio-Rad Laboratories Pty Ltd, 23, 37
bleeding, 49, 57
see also haemophilia and bleeding disorders
blood cells, see red blood cells
Blood Service, see Australian Red Cross Blood Service
BloodNet, 19, 40, 44–45, 63
BloodSafe eLearning Australia, 55
BloodSTAR, 38, 39
Board, 12–14, 146–149
budget, see finance
C
C1 esterase, 40
Change Day, 58
classification of staff, 71, 72–73
rationalisation of levels, 74
clinical demand, see demand
clinical practice guidelines, see Patient Blood Management (PBM) Guidelines
Clinical Transfusion Practice BEA course completions, 55
clotting factors, see Factor VIIa; Factor VIII; Factor IX
Commonwealth Ombudsman, 67
communication and promotion, 50–54, 58
see also information communication technology
competitive tendering and contracting, 84
conferences and sector events, 50–54, 56
consultants, 85
contracts, see purchasing
Corporate Plan, 14, 64
Council of Australian Governments (COAG) Health Council, 3, 41, 81
Criteria for the clinical use of intravenous immunoglobulin in Australia, 38
critical bleeding, 57
see also haemophilia and bleeding disorders
Critical Care PPM Guidelines module, 53
CSL Behring Pty Ltd, 22, 152, 153, 154–155
Fractionation Agreement, 27, 34–35
imports, 35, 37, 154, 155
red cell diagnostic reagent products, 37
Customer Service Charter, 67
D
data developments, 40–41, 57
see also information communication technology
Deed of Agreement, Red Cross, 32–34, 41
deliverables, 18–19
demand, 18, 24–31
platelets, 26, 41
diagnostic reagent products, 23, 37
disability reporting, 160
discards, see wastage
donor management, Blood Service, 33
E
ecologically sustainable development, 157–159
education and training, 54–55
employees, 68, 69–75, 156
enterprise agreement, 72–73
environmental performance, 157–159
exempt contracts, 84
expenditure, see finance
external scrutiny, 67
F
Factor VIIa (rFVIIa), 23, 28, 29
supply contracts, 36, 152
Factor VIII (rFVIII), 27–28
clinical practice guidelines, 48
inhibitor bypass agent (FEIBA), 28, 29, 152
supply contracts, 36, 152, 153
Factor IX (rFIX), 27, 28
clinical practice guidelines, 48
supply contracts, 36, 153
finance, 78–143, 161–162
Audit Committee, 63, 64, 149
Blood Service, 33, 34, 78
grant programmes, 160
see also purchasing
financial assets, 81
financial statements, 86–143
audit report, 80
fractionation, see plasma and recombinant products
fraud control, 68
freedom of information, 160
fresh blood, 21, 24–26, 32–34
components supplied under contract, 151
see also Australian Red Cross Blood Service; patient blood management; platelets;
red blood cells
frozen blood products, 34
functions and role, 2–3, 12
G
gender of staff, 71
General Manager, 3, 62, 63
review of year, 8–11
governance, 62–64
blood sector data and information, 41
immunoglobulin arrangements, 38–39, 63
grant programmes, 160
Grifols Australia, 23, 35, 37
H
haematology, 30, 39
haemophilia and bleeding disorders, 40, 42, 48
MyABDR portal, 42–43
see also Factor VIIa; Factor VIII; Factor IX
haemovigilance, 40
health provider Charter, 66
horizon scanning, 46
human resources, 68, 69–75, 156
I
immunoglobulins (IVIg), 27, 29–31, 154–155
CSL Behring Ltd supplies, 26, 27, 35, 154–155
governance arrangements, 38–39, 63
imported supplies, 22–23, 30, 35–36, 154, 155
immunology, 30, 39
income, see finance
Indigenous employees, 71
information communication technology (ICT), 42–45, 62
BloodNet, 19, 40, 44–45, 63
BloodSafe eLearning Australia, 55
BloodSTAR, 38, 39
Patient Blood Management website pages, 49
Information Publication Scheme statement, 160
internal audit, 63, 64
international horizon scanning, 46
inventory management
Blood Service, 33
BloodNet, 19, 40, 44–45, 63
CSL Behring Ltd, 35, 37
imported intravenous immunoglobulin, 36
imported plasma and recombinant blood products, 37
iron products, 49
J
Johnson & Johnson Medical Pty Ltd, 23, 37
judicial decisions, 67
Jurisdictional Blood Committee (JBC), 39, 40
endorsements and approvals, 40, 41, 47, 57
Strategic Plan, 8, 14, 64
K
key performance indicators,
see performance indicators
L
legal actions, 67
legislation, 3, 12, 68, 78
liabilities, see assets
M
management and accountability, 62–75
see also finance
Management Committee, 62
market research and advertising, 157
Massive Transfusion Registry, 57
Medical PBM Guidelines module, 55
Medical Services Advisory Committee review, 40
Ministers, 3
MyABDR portal, 42–43
N
National Blood Account, 78, 79
National Blood Agreement, 3, 57, 78, 82
evaluations undertaken under Schedule 4, 40
National Blood and Blood Product Wastage Reduction Strategy 2013–2017, 40, 48
National Blood Authority Act 2003, 3, 12, 78
National Blood Authority Board, 12–14, 146–149
National Blood Awards for Excellence in the Management of Blood, 54
National Blood Research and Development Strategic Priorities 2013–2016, 57
National Blood Sector Data and Information Governance Framework, 41
National Blood Sector Data and Information Strategy and Scorecard 2013–2016, 40–41
National Blood Sector Education and Training Strategy 2013– 2016, 54–55
National Blood Sector ICT Strategy 2013–16, 42
National Blood Supply Contingency Plan, 41
National Blood Symposium, 53–54
National Education and Training Committee, 55
National Haemophilia Guidelines, 48
National Haemovigilance Report 2015, 40
National Immunoglobulin Governance Advisory Committee, 39
National Inventory Management Framework, 33
National Managed Fund Action Plan Review, 41
National Managed Fund (Blood and Blood Products) Special Account, 78, 79
National Patient Blood Management Guidelines Implementation Strategy 2013–2017, 48
National Policy Access to Government Funded Immunoglobulin Products in Australia, 39
National Safety and Quality Health Service Standards, 55
National Service Requirements and Standards, 33
National Supply Plan and Budget, 21–31
National Supply List inclusions, 30, 40
Neonatal and Paediatric PPM Guidelines module, 48
neurology, 30, 39
non-English speaking backgrounds, employees from, 71
non-financial assets, 81
non-ongoing staff, 71
normal immunoglobulin (NIg), 31, 154
Novo Nordisk Pharmaceuticals Pty Ltd, 23, 36, 37, 152
O
Obstetrics and Maternity PBM Guidelines module, 19, 53, 56
occupational health and safety, 75, 156
Octapharma Australia Pty Ltd, 23, 35, 36, 154
Ombudsman, 67
ongoing staff, 71
online services, see information communication technology
operating result, 80–82
Blood Service, 33
operational planning, 64–66
organ transplantation, 39
organisation and structure, 2–14, 62–64
organisation chart, 4
Ortho-Clinical Diagnostics, 23, 37
outcome and objectives, 18–58
Output Based Funding Model (OBFM), 24, 32
overseas horizon scanning, 46
P
Parliamentary committees, 67
patient blood management, 19, 47–49, 58
National Blood Awards, 54
Patient Blood Management (PBM) Guidelines, 19, 47–48, 53, 56
BloodSafe eLearning Australia releases based on, 55
companion, 49, 53
Module 1 review, 47, 63
payroll contract, 74
people management, 68, 69–75, 156
performance indicators, 18–19
Australian Red Cross Blood Service, 32–33
CSL Australian Fractionation Agreement, 34–35
environmental performance, 158–159
imported intravenous immunoglobulin, 36
imported plasma-derived and recombinant products, 37
performance pay, 74
performance reporting, 18–58
Pfizer Australia Pty Ltd, 23, 36, 37, 153
planning, 8, 14, 64–66
plasma and recombinant products, 21, 22–23, 27–31
supply contracts, 34–37, 152–155
Supply Risk and Mitigation Project, 42
see also immunoglobulins
plasma for fractionation, 24, 26, 27, 34–35, 151
plasmapheresis, 26, 33, 151
platelets, 26, 41, 151
discards, 50
shelf-life, 34
Preoperative Bleeding Risk Assessment Tool, 49
prices, 24, 26, 27, 151–155
procurement, see purchasing
productivity gains, 74
Project Governance Boards, 63
promotion and communication, 50–54, 58
see also information communication technology
Public Governance, Performance and Accountability Act 2013, 3
Public Governance, Performance and Accountability Rule 2014, 68
Public Service Act 1999, 3
purchasing, 84–85
advertising and market research, 157
payroll contract, 74
purchasing of blood and blood product supply, 3, 21–25, 78–79, 81–82, 151–155
contract management, 18, 32–37
plasma and recombinant products, 21, 22–23, 27, 30, 34–37, 152–155
savings, 8–9, 27; supply contracts, 35, 36
see also inventory management
Q
quality improvement initiatives, see safe and efficient use
Queensland Health, 53
R
recombinant products, see plasma and
recombinant products
red blood cells, 24, 25, 49, 151
data linkage, 41
diagnostic reagent products, 23, 37
discards, 50
inventory management, 33
remuneration of staff, 72–73, 74
Report on the Issue and Use of IVIg 2013–14, 30
research and development, 57
Blood Service, 34
resource statements, 161–162
revenue, see finance
Review of Risk Management in the Blood Sector, 41
risk management, 64
blood sector, 41–42
preoperative bleeding, 49
Rural Medicine Australia 2014 conference, 51–52
S
safe and efficient use, 19, 47–58
expenditure resulting from measures introduced, 27
salary and remuneration, 72–73, 74
satisfaction with Blood Service, 33
savings, 8–9, 24–25, 27
supply contracts, 35, 36
sector monitoring, 46
security of supply, see supply
Senior Executive Management, 62, 63
senior executive service, 73, 74
Service Charter, 67
small business, procurement initiatives to support, 85
solid organ transplantation, 39
special accounts, 78–79
staff, 68, 69–75, 156
stakeholder engagement programme, 13–14
standards, 53, 55
Blood Service, 33
haemovigilance, 40
Statement on national stewardship expectations for the supply of blood and blood products, 10, 48
subcutaneous immunoglobulin (SCIg), 30, 31, 154
supply, 18, 21–37, 151–155
platelet shortage, 41
risk mitigation for plasma and recombinant products project, 42
supply chain management,
see inventory management
T
tenders, see purchasing
training, 54–55
Transfusion Outcomes Research Collaborative, 57
transfusions, 49, 55, 57, 58
tribunal decisions, 67
V
values, 70
W
wastage (discards), 40, 50
reduction strategy, 40, 48
website services, see information communication technology
whole blood, 26, 33, 151
work health and safety, 75, 156